Gossamer Bio Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.9344
- Today's High:
- $1.01
- Open Price:
- $0.982
- 52W Low:
- $0.91
- 52W High:
- $14.57
- Prev. Close:
- $0.97
- Volume:
- 1384511
Company Statistics
- Market Cap.:
- $236.59 million
- Book Value:
- -0.658
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -59.8%
- Return on Equity TTM:
- -25925.78%
Company Profile
Gossamer Bio Inc had its IPO on 2019-02-08 under the ticker symbol GOSS.
The company operates in the Healthcare sector and Biotechnology industry. Gossamer Bio Inc has a staff strength of 178 employees.
Stock update
Shares of Gossamer Bio Inc opened at $0.98 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.93 - $1.01, and closed at $0.95.
This is a -2.14% slip from the previous day's closing price.
A total volume of 1,384,511 shares were traded at the close of the day’s session.
In the last one week, shares of Gossamer Bio Inc have slipped by -9.6%.
Gossamer Bio Inc's Key Ratios
Gossamer Bio Inc has a market cap of $236.59 million, indicating a price to book ratio of 4.0908 and a price to sales ratio of 0.
In the last 12-months Gossamer Bio Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-202712000. The EBITDA ratio measures Gossamer Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Gossamer Bio Inc’s operating margin was 0% while its return on assets stood at -59.8% with a return of equity of -25925.78%.
In Q2, Gossamer Bio Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Gossamer Bio Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Gossamer Bio Inc’s profitability.
Gossamer Bio Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.7392. Its price to sales ratio in the trailing 12-months stood at 0.
Gossamer Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $181.75 million
- Total Liabilities
- $40.14 million
- Operating Cash Flow
- $12.94 million
- Capital Expenditure
- $15000
- Dividend Payout Ratio
- 0%
Gossamer Bio Inc ended 2024 with $181.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $181.75 million while shareholder equity stood at $-62800000.00.
Gossamer Bio Inc ended 2024 with $0 in deferred long-term liabilities, $40.14 million in other current liabilities, 10000.00 in common stock, $-1123884000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $37.00 million and cash and short-term investments were $162.13 million. The company’s total short-term debt was $14,753,000 while long-term debt stood at $202.58 million.
Gossamer Bio Inc’s total current assets stands at $173.38 million while long-term investments were $0 and short-term investments were $125.12 million. Its net receivables were $0 compared to accounts payable of $2.21 million and inventory worth $0.
In 2024, Gossamer Bio Inc's operating cash flow was $12.94 million while its capital expenditure stood at $15000.
Comparatively, Gossamer Bio Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.95
- 52-Week High
- $14.57
- 52-Week Low
- $0.91
- Analyst Target Price
- $6.45
Gossamer Bio Inc stock is currently trading at $0.95 per share. It touched a 52-week high of $14.57 and a 52-week low of $14.57. Analysts tracking the stock have a 12-month average target price of $6.45.
Its 50-day moving average was $1.23 and 200-day moving average was $1.83 The short ratio stood at 7.33 indicating a short percent outstanding of 0%.
Around 539.7% of the company’s stock are held by insiders while 9036.9% are held by institutions.
Frequently Asked Questions About Gossamer Bio Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.